{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:29:53Z","timestamp":1774675793847,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.anl.2020.01.003","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T07:59:19Z","timestamp":1580889559000},"page":"650-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma"],"prefix":"10.1016","volume":"47","author":[{"given":"Hiroto","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Shirasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Notsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Onitsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2020.01.003_bib0001","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.01.003_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.01.003_bib0003","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2020.01.003_bib0004","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment - a review from the melanoma perspective and beyond","volume":"9","author":"Buder-Bakhaya","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.anl.2020.01.003_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with antiPD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.anl.2020.01.003_bib0006","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anl.2020.01.003_bib0007","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.anl.2020.01.003_bib0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.otorri.2011.06.004","article-title":"Predictive ability of the CT to evaluate cervical lymph nodes in head and neck tumours","volume":"62","author":"I\u00f1arra Unzurrunzaga","year":"2011","journal-title":"Acta Otorrinolaringol Esp"},{"key":"10.1016\/j.anl.2020.01.003_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12070-015-0837-4","article-title":"Diagnostic efficacy of computed tomography in detecting cervical metastases in clinically N0 head and neck squamous cell carcinoma","volume":"68","author":"Bhargava","year":"2016","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2020.01.003_bib0010","doi-asserted-by":"crossref","first-page":"e83492","DOI":"10.1371\/journal.pone.0083492","article-title":"Spectral CT imaging of laryngeal and hypopharyngeal squamous cell carcinoma: evaluation of image quality and status of lymph nodes","volume":"8","author":"Li","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.anl.2020.01.003_bib0011","first-page":"25","article-title":"Neck dissection: current status and future possibilities","volume":"11","author":"Shah","year":"1981","journal-title":"Clin Bull"},{"key":"10.1016\/j.anl.2020.01.003_bib0012","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.0.CO;2-O","article-title":"Tutorial in biostatistics categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments","volume":"19","author":"Mazumdar","year":"2000","journal-title":"Statist Med"},{"key":"10.1016\/j.anl.2020.01.003_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018ezr\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.anl.2020.01.003_bib0014","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2020.01.003_bib0015","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anl.2020.01.003_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.anl.2020.01.003_bib0017","doi-asserted-by":"crossref","first-page":"abstr.6009","DOI":"10.1200\/JCO.2018.36.15_suppl.6009","article-title":"A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)","volume":"36","author":"McBride","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl.1","key":"10.1016\/j.anl.2020.01.003_bib0018","first-page":"E1068","article-title":"Neutrophil-to-lymphocyte ratio and overall survival in all sites of head and neck squamous cell carcinoma","volume":"38","author":"Rachidi","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2020.01.003_bib0019","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/hed.24986","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: a meta-analysis","volume":"40","author":"Takenaka","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2020.01.003_bib0020","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/hed.25737","article-title":"Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer","volume":"41","author":"Yasumatsu","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2020.01.003_bib0021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anl.2020.01.003_bib0022","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00405-019-05323-w","article-title":"Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas","volume":"276","author":"Bohlen","year":"2019","journal-title":"European Archives of Oto-Rhino-Laryngology"},{"issue":"Suppl.6","key":"10.1016\/j.anl.2020.01.003_bib0023","first-page":"328","volume":"27","author":"Argiris","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl.8","key":"10.1016\/j.anl.2020.01.003_bib0024","first-page":"LBA8","article-title":"KEYNOTE048: phase III study of first-line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"29","author":"Burtness","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl.15","key":"10.1016\/j.anl.2020.01.003_bib0025","doi-asserted-by":"crossref","first-page":"TPS6101","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS6101","article-title":"A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) \u00b1 tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent\/metastatic (R\/M) SCCHN: KESTREL","volume":"34","author":"Seiwert","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anl.2020.01.003_bib0026","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814620300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814620300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:37:15Z","timestamp":1759952235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814620300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0385814620300237"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2020.01.003","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2020.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}